Results 41 to 50 of about 9,834 (223)
Widening use of dexamethasone implant for the treatment of macular edema [PDF]
, 2017 Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T. +9 more
core +2 more sources
Pseudophakic macular edema involving epiretinal proliferation associated with macular hole
Indian Journal of Ophthalmology, 2020 This case report describes an unusual course of an impending macular hole (MH) throughout a 72-month follow-up period. A 53-year-old female presented with impending MH associated with epiretinal proliferation (EP) which showed unusual progress including ...
Figen Batioglu +3 more
doaj +1 more source
Dexamethasone Implant Migration through an Iris Coloboma
Case Reports in Ophthalmology, 2020 Ozurdex® 0.7 mg (dexamethasone 0.7 mg implant, Allergan, Dublin, Ireland), an intravitreal biodegradable implant, is indicated for cystoid macular edema due to various causes.
Yoav Glidai +2 more
doaj +1 more source
InterConf, 2023 One of the serious vision threatened complications of cataract surgery is refractory PCME. That is why this complication has to be managed in time and adequately.
H. Gahramanov +3 more
semanticscholar +1 more source
Case Reports in Ophthalmology, 2023 Dexamethasone intravitreal implant (Ozurdex®; Allergan, Inc., CA, USA) has been proved to be effective in a variety of clinical settings including cases of pseudophakic cystoid macular edema.
Panagiotis Stavrakas +5 more
doaj +1 more source
Dexamethasone Intravitreal Implant for Treatment of Patients with Recalcitrant Macular Edema Resulting from Irvine-Gass Syndrome [PDF]
, 2013 PURPOSE: To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant, over 6 months in patients with recalcitrant CME due to Irvine-Gass syndrome. METHODS: Retrospective review of the medical records of nine patients with
Corcóstegui, B +4 more
core +1 more source
Fingolimod-associated severe bilateral cystoid macular edema
American Journal of Ophthalmology Case Reports, 2022 Purpose: To report a rare case in which a patient undergoing long-term oral fingolimod treatment for multiple sclerosis (MS) developed late-onset severe bilateral cystoid macular edema (ME) at 3-weeks post cataract surgery.
Hideki Fukuoka +4 more
doaj +1 more source
Cataract surgery in uveitis:a multicentre database study [PDF]
, 2017 BACKGROUND/AIMS: Cataract is an important source of visual loss in patients with uveitis. Whether or not outcomes of cataract surgery in eyes with uveitis are worse compared with non-uveitic eyes have to date been compromised by lack of reliable ...
, +5 more
core +5 more sources
Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography [PDF]
, 2013 Purpose: To correlate inflammatory and proangiogenic key cytokines from undiluted vitreous of treatment-naïve central retinal vein occlusion (CRVO) patients with SD-OCT parameters. Methods: Thirty-five patients (age 71.1 years, 24 phakic, 30 nonischemic)
Cinatl, Jindrich +8 more
core +1 more source
Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report [PDF]
, 2016 Background Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon ...
AGOSTINELLI, Enzo +6 more
core +1 more source